Rate My Professor Sabatino Ventura

Ventura's research specializes in the pharmacology of the male reproductive system, particularly the development of novel, non-hormonal male contraceptives. His group targets the P2X1 purinoceptor to pharmacologically block sperm transport in the epididymis and vas deferens, providing a reversible option that does not affect sperm production or sexual health. Notable projects under his leadership or supervision include "Development of a P2X1 receptor antagonist for use as a male contraceptive" (2025–2027), "Discovery of a lead molecule for development into a non-hormonal male contraceptive" (2023–2024), "Male contraception through pharmacological blockade of sperm transport" (2018–2020), and "Assessment of the Suitability of a Lipid Extract of Saw Palmetto for the Treatment of Benign Prostatic Hyperplasia" (2010–2011). His publication record comprises 63 articles, 20 abstracts, 2 review articles, and 1 short review. Prominent works include "Structural insights into the human P2X1 receptor and ligand interactions" (Nature Communications, 2024), "The P2X1 receptor as a therapeutic target" (Purinergic Signalling, 2022), "Aqueous extracts of Urtica dioica leaf contain a P2-purinoceptor antagonist—Implications for male fertility" (PLoS ONE, 2022), "Synthesis of 2-phenyl-5,6,7,8-tetrahydroquinoxaline derivatives and screening for P2X1-purinoceptor antagonist activity in isolated preparations of rat vas deferens, for translation into a male contraceptive" (Biology of Reproduction, 2020), and "Male contraception via simultaneous knockout of α1A-adrenoceptors" (PNAS, 2013). In 2024, he was a recipient of the Faculty of Pharmacy and Pharmaceutical Sciences Award for Programs that Enhance Learning. His research aligns with UN Sustainable Development Goal 3: Good Health and Well-being.